News – Page 594 – Endpoints News

The big shakeup at a badly rattled Biogen continues as 2 longtime board members hit the exits

4 years ago

In pledging to vote for Rob Califf, Elizabeth Warren takes a swing at the FDA-industry revolving door

4 years ago

Mark Cuban's new cost-plus-15% generic drug company is really a compounding pharmacy

4 years ago

The FDA approves Moderna's revolutionary new Covid-19 vaccine. What took so long?

4 years ago

Troubled cancer center in Connecticut handed Form 483 by FDA, again

4 years ago

Which FDA guidance documents are coming for drugmakers in 2022? Agency unveils new lists

4 years ago

MarketingRx Matchup: GlaxoSmithKline, AstraZeneca asthma TV ads face off in consumer ratings

4 years ago

Chinese agency says suspects arrested in AstraZeneca insurance fraud probe

4 years ago

A NASH player touts positive PhIII data, but true test still lies ahead

4 years ago

Covid-19 roundup: Non-Covid PhIII trials saw steep decline in 2020; Merck's pill is last choice among patients

4 years ago

As sirens blare on biotech public markets, small cell therapy player Gamida plans to axe 10% of staff

4 years ago

Cryo-EM focused biotech from longtime NIH veteran secures $40M backing from Bayer in Series A

4 years ago

Waking up from some big blockbuster dreams, Pfizer scraps a $250M drug deal as data sour, safety fears rise

4 years ago

UK biotechs smash 2020 investment records, surpassing San Diego in VC and IPO raises

4 years ago

FDA clears Roche’s bispecific Eylea contender, but can it compete with the Regeneron blockbuster?

4 years ago

The Covid-19 vaccine IP waiver is back at the WTO, with a new deadline. Can it muster enough support?

4 years ago

'Thoroughly f*****d' for cyberattacks?; Bad week for drug developers; The next big I/O breakthrough?; Biogen does a ...

4 years ago

Cybersecurity experts warn biopharma industry is not prepared for the next big attack: 'We are thoroughly f****d'

4 years ago

Massive $1.5B investment in manufacturing widens Eli Lilly's footprint in Ireland and North Carolina

4 years ago

Merck enlists HPV-related cancer survivors and physicians in social and digital ‘Story’ campaign

4 years ago

Flagship startup brings out the budget ax, chops staff and clinical plans as share price flounders

4 years ago

Regeneron and Sanofi pull Libtayo app in cervical cancer, citing post-market study disagreement with FDA

4 years ago

Of course the market debacle will influence M&A, dealmaking. The pendulum is swinging back to buyers

4 years ago

As pockets fill with cash, Maravai spends $240M to ensure pure mRNA production

4 years ago

First page Previous page 591 592 593594595 596 597 Next page Last page